Kānuka (Kunzea ericoides complex) is a New Zealand native tree in the myrtle family (Myrtaceae) that grows across both islands from coastal scrub up to subalpine bush. The plant is field-confused with mānuka (Leptospermum scoparium) — the two share the family, the bush, the small white flowers, and a similar growth form — but they are different genera, and the de Lange 2014 PhytoKeys monograph split the broader Kunzea ericoides complex into ten New Zealand species (K. ericoides, K. linearis, K. amathicola, K. robusta, K. salterae, K. serotina, K. sinclairii, K. tenuicaulis, K. toelkenii, K. triregensis). For honey purposes, kānuka honey comes from across this complex; the regional and species variation is real but rarely tracked at the commercial label tier.
The honey is its own product. Kānuka monofloral is pale to light amber, lighter than typical mānuka, with a softer floral lift and a slightly fruity middle that distinguishes it from the eucalyptol-and-herbaceous register that mānuka carries. The texture is liquid; crystallization is moderate; the honey is approachable in a way mānuka often is not.
Not high in MGO. The defining science fact about kānuka honey is that its antibacterial activity runs on the hydrogen peroxide / phenolic pathway shared with most honey — the same chemistry that gives clover, wildflower, and acacia their baseline activity. It is not the methylglyoxal (MGO) pathway that gives mānuka its certified non-peroxide activity. Lu et al. (2013, PLoS One) measured antibacterial activity across a broad New Zealand honey set and found that activity in kānuka and most other honeys was peroxide-dependent and broadly equal — not differentially superior. The clinical Rule on this page is clean: UMF and MGO grades are inapplicable to kānuka honey. A jar of kānuka labeled "UMF 10+" is either mislabeled or borrowing manuka's grading inappropriately.
The clinical record (research-voiced). Two New Zealand BMJ Open RCTs frame the kānuka clinical literature:
- Braithwaite et al. 2015 (BMJ Open) tested a medical-grade kānuka-honey formulation (Honevo) against placebo for rosacea and found significant improvement on the IGA-RSS scale. The study was on the formulation, not "kānuka honey heals rosacea" — Honevo is 90% medical-grade kānuka with 10% glycerin, manufactured for topical use, not a kitchen-cupboard product.
- Semprini et al. 2016 (BMJ Open) tested the same Honevo formulation against placebo for facial acne and found no significant difference.
Both trials are real, both are on the same formulation, and the two-direction story — positive on rosacea, negative on acne — is the honest research-voiced framing. We do not extend the formulation results to "kānuka honey treats rosacea" as a general claim.
Plant-vs-honey firewall. Kunzea ericoides leaf essential oil is a separate product from the honey. The leaf-distilled oil carries terpenoids (α-pinene, 1,8-cineole, viridiflorol) at activity-relevant concentrations and has its own ethnopharmacology literature. The honey carries trace levels at best — bee-foraged nectar does not concentrate leaf-tissue terpenoids. Claims about kānuka oil's antimicrobial or anti-inflammatory action do not transfer to the honey.
Threat: myrtle rust. Austropuccinia psidii (myrtle rust) reached New Zealand in 2017 and is a significant ongoing threat to both kānuka and mānuka populations. The pathogen is now established on the North Island and has reached parts of the South Island. The kānuka honey supply chain depends on long-term plant health that myrtle rust has materially affected; this is part of why the variety reads as ecologically embedded rather than industrially scaled.
